Search Press releases Keywords From To 26 Mar 2022 New Long-Term Complete Skin Clearance Data for BIMZELX[®]▼ (bimekizumab) in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting Read More 25 Mar 2022 Disposal of own shares Read More 25 Mar 2022 New UCB data analysis adds to demonstrated efficacy of romosozumab▼ to reduce the risk of fractures Read More 25 Mar 2022 WCO-IOF-ESCEO 2022 – Post-hoc analysis on the proportion of patients treated with EVENITY[® ]▼(romosozumab) reaching surrogate threshold effect that predicts fracture risk reduction Read More 18 Mar 2022 Transparency notification FMR LLC Read More 18 Mar 2022 Disposal of own shares Read More Pagination First page Previous page Previous … Page 37 Page 38 Page 39 Page 40 Current page 41 Page 42 Page 43 Page 44 Page 45 … Page 41 of 71 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
